Secukinumab is effective in treatment of moderate‐to‐severe plaque psoriasis: real‐life effectiveness and safety from the PROSPECT study-Reference-Cited by-同舟云学术

Secukinumab is effective in treatment of moderate‐to‐severe plaque psoriasis: real‐life effectiveness and safety from the PROSPECT study

Published:2019-10-17 Issue:2 Volume:34 Page:310-318
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venereol

Author:

Thaçi D.¹,Körber A.²,Kiedrowski R.³,Bachhuber T.⁴,Melzer N.⁴,Kasparek T.⁴,Duetting E.⁴,Kraehn‐Senftleben G.⁵,Amon U.⁶,Augustin M.⁷^ORCID

Affiliation:

1. Comprehensive Centre of Inflammation Medicine University of Lübeck Lübeck Germany

2. Department of Dermatology University Hospital Essen Essen Germany

3. Dermatologische Spezialpraxis Selters Germany

4. Novartis Pharma GmbH Nürnberg Germany

5. Hautzentrum Donau Alb Blaubeuren Germany

6. International Centre for Skin Disease DermAllegra Hohenstadt/Nürnberg Germany

7. Institute for Health Services Research in Dermatology and Nursing (IVDP) German Centre for Health Services Research in Dermatology (CVderm) University Medical Center Hamburg‐Eppendorf (UKE) Hamburg Germany

Funder

Novartis Pharma

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.15962

Reference16 articles.

1. German S3-guidelines on the treatment of psoriasis vulgaris (short version)

2. S3‐guidelines for the treatment of psoriasis vulgaris Update 2011;Nast A;J Dtsch Dermatol Ges,2011

3. A consensus report on appropriate treatment optimization and transitioning in the management of moderate‐to‐severe plaque psoriasis

4. The role of IL‐17 in the pathogenesis and treatment of psoriasis;Zeichner JA;J Clin Aesthet Dermatol,2016

5. Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials;Clinical, Cosmetic and Investigational Dermatology;2024-04

2. Deep resolution of clinical, cellular and transcriptomic inflammatory markers of psoriasis over 52 weeks of interleukin-17A inhibition by secukinumab;Clinical and Experimental Dermatology;2024-01-18

3. Long‐term secukinumab efficacy and safety in bio‐naïve patients with moderate‐to‐severe cutaneous psoriasis: A real‐world retrospective noninterventional multicentric experience (128 patients);JEADV Clinical Practice;2023-05-27

4. Sustained Effectiveness of Secukinumab Across Different Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis from the PURE Registry;Dermatology and Therapy;2022-12-23

5. The Use of IL-17 and IL-23 Inhibitors in Swedish Clinical Practice: A Register-Based Analysis;Dermatology;2022-12-14